Condition: Solid Tumor · Non-Small Cell Lung Cancer · Head and Neck Cancer · Sponsor: Inhibrx Biosciences, Inc
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
This description comes directly from the study's public registry record.
Study Director - Inhibrx Biosciences, Inc · 858-500-7833 · clinicaltrials@inhibrx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Los Angeles Cancer Network | Glendale, California, United States | Recruiting |
| California Research Institute | Los Angeles, California, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Valkyrie Clinical Trials | Murrieta, California, United States | Recruiting |
| Providence Medical Foundation | Santa Rosa, California, United States | Recruiting |
| Clermont Oncology Center | Clermont, Florida, United States | Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City, Florida, United States | Recruiting |
| Winship Cancer Institute - Emory University | Atlanta, Georgia, United States | Recruiting |
| The University of Chicago Medical Center | Chicago, Illinois, United States | Active Not Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Active Not Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Recruiting |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04198766